Common questions about Butorgesic (FAQ)
Q: Is Butorgesic available without a prescription in some countries?
According to official US regulatory documents, Butorgesic (butorphanol tartrate) is categorized as a Schedule IV controlled substance. This designation means it is strictly a prescription-only medication and cannot be obtained over the counter.
Q: Can Butorgesic be used by children?
Official prescribing information states that the safety and effectiveness of Butorgesic have not been established in pediatric patients (children). Because the safety and effectiveness is not established, regulatory documents advise against use in pediatric populations.
Q: Can Butorgesic cause weight gain or loss?
While weight gain is not listed as a reported side effect in official documents, studies have reported weight loss as an infrequent adverse reaction. Any unexpected or significant body changes are typically reported to a prescribing healthcare professional.
Q: Can I take Butorgesic if I am already taking blood pressure medication?
Regulatory documents indicate that Butorgesic can potentially affect the heart and blood vessels, with reported effects including both hypotension (low blood pressure) and hypertension (high blood pressure). These potential effects mean that the use of Butorgesic alongside blood pressure medication is a matter for clinical evaluation and monitoring.
Q: Is it necessary to stop taking Butorgesic before surgery?
The injectable form of the drug has an official indication for use as a pre-anesthetic or preoperative medication and can be used to supplement balanced anesthesia. However, the nasal spray formulation is generally not studied or recommended for these specific anesthetic uses. The decision to use Butorgesic for these purposes is a clinical one, consistent with official use conditions.
Q: How long does it usually take to notice any effect from Butorgesic?
Official pharmacology documents provide estimates for the onset of analgesia (pain relief) depending on the route of administration. For intravenous (IV) injection, effects may be noticed within a few minutes, while intramuscular (IM) injection and nasal spray administration generally show an effect within 15 minutes.
Q: Is it described in official sources how long a person should use Butorgesic?
Official warnings discuss risks associated with use for extended periods of time, typically defined as longer than one month. These long-term risks include the potential for Adrenal Insufficiency and Androgen Deficiency. This indicates that the risks associated with extended use are recognized and monitored by healthcare professionals.
Q: What happens if I suddenly stop taking Butorgesic?
Official warnings advise that Butorgesic may cause withdrawal symptoms in people who are physically dependent on opioid medications. Because of its mixed mechanism of action, it can precipitate these effects, which may include symptoms like anxiety, agitation, and diarrhea.
Q: Are there different brand names for the same active ingredient in Butorgesic?
The active ingredient in Butorgesic is butorphanol tartrate. This substance was previously marketed in the United States under the brand name Stadol, although that specific brand name has since been discontinued.
Q: Does Butorgesic contain lactose or gluten?
An examination of the inactive ingredients for the injectable solution shows that it does not contain lactose or gluten. However, inactive ingredients like citric acid, sodium chloride, and benzethonium chloride are listed. The complete list of excipients (inactive ingredients) for the specific formulation being administered is provided for review.
Q: Why is it described in official documents that Butorgesic may not be suitable for people with heart conditions?
Regulatory documents report that Butorgesic has been shown to cause changes in the function of the heart and blood vessels, known as hemodynamic changes, in patients with heart disease. These changes can include an increase in pulmonary artery pressure and systemic arterial pressure.
Q: What is the difference between immediate-release and extended-release forms of Butorgesic, if both exist?
Butorgesic is officially available as an injectable solution for intravenous and intramuscular use and as an aqueous nasal spray solution. Neither of these two primary forms is currently classified or described in regulatory documents as an extended-release product.
Q: Is it normal to feel a bit restless after taking Butorgesic?
Official labels list agitation as a less frequent adverse experience and tremor (shaking) as a common adverse experience. These reported neurological effects may be what contribute to a feeling of restlessness in some individuals.
Q: Are there known interactions between Butorgesic and birth control pills?
Official labels do not explicitly list a specific interaction between Butorgesic and birth control pills. However, chronic opioid use may cause hormonal changes that lead to reduced fertility in both men and women.
Q: How does a person report a side effect they experienced with Butorgesic?
Patients and healthcare providers are officially advised by regulatory agencies to report any side effects or serious adverse events related to the medication. This is typically facilitated through official reporting programs, such as the FDA’s MedWatch program in the US.
Q: Is there a risk of overdose described in official documents for Butorgesic?
Yes, the risk of acute overdose is documented in official warnings. Overdose manifestations include life-threatening respiratory depression, which is the most serious concern, and may progress to coma. The risk of a fatal overdose is emphasized, especially from accidental ingestion.
Q: What is the role of a pharmacist when discussing Butorgesic?
Pharmacists play a critical role in ensuring safe use by helping to provide important documents, such as the Medication Guide. They may also be involved in ensuring that patients have access to the opioid overdose reversal agent naloxone, which is often encouraged for patients using opioids.
Q: What happens if I accidentally take two doses of Butorgesic too close together?
Taking more than the prescribed amount significantly increases the risk of serious side effects. Regulatory documents emphasize that the risk of potentially fatal respiratory depression is greatest following any dosage increase or when first starting therapy.
Q: Is Butorgesic considered a controlled substance in some regions?
Yes, Butorgesic (butorphanol tartrate) is recognized by regulatory bodies as a controlled substance. In the United States, it is designated as a Schedule IV drug by the DEA, reflecting its potential for abuse and dependence.
